4//SEC Filing
Leggett Thomas 4
Accession 0000899243-20-033341
CIK 0001701541other
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 4:16 PM ET
Size
11.3 KB
Accession
0000899243-20-033341
Insider Transaction Report
Form 4
Leggett Thomas
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2020-12-08$10.86/sh+3,000$32,580→ 3,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-08−3,000→ 221,171 totalExercise: $10.86Exp: 2029-09-08→ Common Stock (3,000 underlying) - Sale
Common Stock
2020-12-08$33.27/sh−1,059$35,233→ 1,941 total - Sale
Common Stock
2020-12-08$34.05/sh−1,941$66,094→ 0 total
Footnotes (4)
- [F1]Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.72 to $33.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.75 to $34.375, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
Documents
Issuer
Black Diamond Therapeutics, Inc.
CIK 0001701541
Entity typeother
Related Parties
1- filerCIK 0001774690
Filing Metadata
- Form type
- 4
- Filed
- Dec 9, 7:00 PM ET
- Accepted
- Dec 10, 4:16 PM ET
- Size
- 11.3 KB